NCT03072043 · OUTCOME

Phase 2: Overall Response Rate

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms · Source last updated 2022-01-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percent of participants
Interval / dispersion: 95% Confidence Interval
Time frame: Up to 24 months

What was measured

Proportion of participants achieving hematological improvement (HI), partial response (PR), complete response (CR), and/or marrow CR (mCR) by the IWG 2006 criteria.

Analysis population: 45 participants were evaluable for response

Groups in this outcome

All Participants

All participants

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Participants	45

Reported measurements

Source class 1

Values in percent of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
All Participants	87	Not reported	73	95	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
73
upper Limit
95
value
87

denoms

counts
group Id
OG000
value
45
units
Participants

description

Proportion of participants achieving hematological improvement (HI), partial response (PR), complete response (CR), and/or marrow CR (mCR) by the IWG 2006 criteria.

dispersion Type

95% Confidence Interval

groups

description
All participants
id
OG000
title
All Participants

param Type

NUMBER

population Description

45 participants were evaluable for response

reporting Status

POSTED

time Frame

Up to 24 months

title

Phase 2: Overall Response Rate

type

SECONDARY

unit Of Measure

percent of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice